Development Revenue was Adaptimmune Therapeutics’s largest product and service line in fiscal 2024, bringing in $176.80M of $178.03M (99%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Development Revenue | $6.15M | $27.15M | $60.28M | $176.80M | |||||
| License Revenue | — | — | — | — | |||||
| Product Revenue, Net | — | — | — | $1.24M | |||||
| Total | $6.15M | $27.15M | $60.28M | $178.03M |
Adaptimmune Therapeutics brought in $178.03M from its two product and service lines in fiscal 2024, the year ended December 31, 2024. Adaptimmune Therapeutics regrouped these lines after fiscal 2023, so the total does not compare directly with that year's $60.28M. Development Revenue was the largest at $176.80M (99.3%), ahead of Product Revenue, Net at $1.24M (0.7%).
Adaptimmune Therapeutics began breaking out Product Revenue, Net in fiscal 2024, when it brought in $1.24M.
Adaptimmune Therapeutics (ADAPY) reports its revenue by product and service. In fiscal 2024, Development Revenue was its largest product and service line, bringing in $176.80M (99.3% of the total), followed by Product Revenue, Net at $1.24M (0.7%).
Development Revenue was Adaptimmune Therapeutics' largest product and service line in fiscal 2024, bringing in $176.80M, or 99.3% of the $178.03M total across its two product and service lines.
Every figure comes from Adaptimmune Therapeutics' annual financial filings, as reported. Each line keeps the name Adaptimmune Therapeutics gives it, and years follow its fiscal calendar.
Adaptimmune Therapeutics' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.